India: Gland Pharma Q1 Net Profit Rises 47% to ₹317 Crore, Revenue Up 20% to ₹1,800 Crore

Total revenue for the Hyderabad-based company increased 20% to ₹1,800 crore, compared with ₹1,505 crore a year earlier. Executive Chairman Srinivas Sadu attributed the growth to successful execution of the Contract Development and Manufacturing Organisation (CDMO) strategy and strong customer demand, driven by recent product launches and a diversified product mix. The company plans to strengthen its growth platform through a robust CDMO pipeline, including investments in differentiated technologies and capacity expansions.

The results were announced in a release on Monday. Strong performance driven by product launches and robust demand in the CDMO segment signals a promising outlook for the fiscal year ahead.